Clinical trials: Stage IA NSCLC
Lung Cancer
S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers…
- Trial name
- NCT00450281
- Testing
- chromogenic in situ hybridization, gene expression analysis, mutation analysis
- Where
- 405 sites in United States
- Volunteers
- 981 people
- Sponsor
- SWOG Cancer Research Network
Non-small Cell Lung Cancer
Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer
This is a prospective, single arm study to investigate the efficacy and safety furmonertinib 80mg/d as adjuvant treatment for 3 years post surgery of stage IA with high-risk factors and stage IB non-small cell lung cancer.
- Trial name
- NCT05445310
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Peking Union Medical College Hospital
Non Small Cell Lung Cancer, Stage I Lung Cancer
High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer
This trial studies how well high dose vitamin A compound works in treating participants with non-small cell lung cancer that can be removed by surgery.
- Conditions
- Non Small Cell Lung Cancer, Stage I Lung Cancer, Stage Ib Lung Carcinoma, Stage IA Lung Carcinoma AJCC V7
- Trial name
- NCT03870529
- Testing
- Vitamin A Compound, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7
Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer
This pilot clinical trial studies the effects of stereotactic body radiation therapy followed by surgery in treating patients with stage I-IIIA non-small cell lung cancer.
- Conditions
- Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03348748
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer, Dermatologic Complications
S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride
RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride.
- Conditions
- Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
- Trial name
- NCT01416688
- Testing
- assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment
- Where
- 113 sites in United States
- Volunteers
- 146 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
This pilot clinical trial studies how well radiofrequency ablation works in treating patients with stage IA non-small cell lung cancer. Radiofrequency ablation uses high-frequency electric current to kill tumor cells.
- Trial name
- NCT00109876
- Testing
- Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation
- Where
- 17 sites in United States
- Volunteers
- 54 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Small-Cell Lung Cancer
Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer
Background: Pioglitazone is a drug that belongs to the class of antidiabetic agents called thiazolidinediones. It is approved for treatment of type 2 diabetes mellitus.
- Trial name
- NCT00923949
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Lung Neoplasms, Lymph Node Excision
Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
Lung cancer is the leading cause of cancer related death worldwide. Lobectomy or sub-lobectomy with mediastinal lymph node dissection is the standard surgery. About 50% lung nodules are pure ground-glass or part-solid nodules.
- Trial name
- NCT04631770
- Testing
- Systemic mediastinal lymph node dissection, Spared mediastinal lymph node dissection
- Where
- China
- Volunteers
- 1,362 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer Metastatic
MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer
MIDRIX4-LUNG is a novel tetravalent autologous dendritic cell vaccine in metastatic non-small cell lung cancer patients. This first-in-human study aims to primarily establish maximal tolerated dose of MIDRIX4-LUNG administered…
- Trial name
- MIDRIX4-LUNG (NCT04082182)
- Testing
- Dendritic cell immunotherapy, Antigen-specific DTH, Control DTH
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- University Hospital, Ghent
Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer
This clinical trial studies nanoscale artificial nose (NA-NOSE) in monitoring response and detecting recurrence after surgery or radiation therapy in patients with stage I or stage II non-small cell lung cancer (NSCLC).
- Conditions
- Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer
- Trial name
- NCT01840150
- Testing
- breath test, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Fox Chase Cancer Center
Breast Cancer, Colorectal Cancer
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
RATIONALE: Memantine hydrochloride may help people stop smoking by decreasing the symptoms of nicotine withdrawal. PURPOSE: This randomized, pilot phase II trial studies how effective memantine hydrochloride works compared to…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT01535040
- Testing
- memantine hydrochloride
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Wake Forest University Health Sciences
Solid Tumors, Non-Small Cell Lung Cancer
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
This is a phase 1a/1b, open-label, multicenter, dose-escalation and dose-expansion study evaluating the safety, tolerability, antitumor activity, pharmacokinetics, and pharmacodynamics of FXB0871 monotherapy in adults with…
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT07558200
- Testing
- Intervention1：FXB0871, Intervention2：FXB0871, Intervention3：FXB0871
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Stage I Lung Cancer, Stage I Non-Small Cell Lung Cancer AJCC v7
Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy
This trial studies how well fludeoxyglucose F-18 - positron emission tomography (PET) works in planning radiation therapy in participants with early non-small cell lung cancer, early stage lung cancer, or cancer that has spread…
- Conditions
- Stage I Lung Cancer, Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Trial name
- NCT03493789
- Testing
- Fludeoxyglucose F-18, Positron Emission Tomography (PET), Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Emory University
Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation
This is a single-arm, multicenter, open-label, Phase 1a/1b dose-escalation and dose-expansion study designed to evaluate the safety, preliminary antitumor activity, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of…
- Conditions
- Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Adenocarcinoma, Lung Adenocarcinoma
- Trial name
- NCT07875920
- Testing
- Fludarabine, Cyclophosphamide, NW-301V
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Neowise Biotechnology
Lung Cancer
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00792701
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 147 sites in United States
- Volunteers
- 85 people
- Sponsor
- SWOG Cancer Research Network
Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer
This randomized clinical trial studies enhanced quitline intervention in smoking cessation for patients with non-metastatic lung cancer.
- Conditions
- Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
- Trial name
- NCT01457469
- Testing
- questionnaire administration, quality-of-life assessment, counseling intervention
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wake Forest University Health Sciences
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 36 sites in United States, Australia and 8 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Squamous Non-Small Cell Lung Cancer sqNSCLC
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC Patients
The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) combination with Ivonescimab in patients with sq-NSCLC.
- Trial name
- NCT07614646
- Testing
- EVM14, Ivonescimab
- Volunteers
- 13 people
- Sponsor
- Everest Medicines (Beijing) Co., Ltd.
Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Carcinoma
Yoga in Improving Quality of Life in Patients With Non-small Cell Lung Cancer Undergoing Treatment
The purpose of this research study is to evaluate the effects of yoga (including breathing exercises) on the quality of life in patients, diagnosed and undergoing standard treatments for non-small cell lung cancer.
- Trial name
- NCT02895503
- Testing
- Yoga, Support Group Therapy, FACT-L
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Virginia Commonwealth University
Carcinoma, Non-Small-Cell Lung
Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer
A phase II, multicenter, randomized trial of 3D Radiotherapy versus 3D Radiotherapy and erlotinib (Tarceva®) in patients with localized-unresectable (IA-IIIB) non-small cell lung cancer non susceptible for chemotherapy treatment…
- Trial name
- NCT00466089
- Testing
- Erlotinib (Tarceva®)
- Where
- 5 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Hospital of Navarra